247 related articles for article (PubMed ID: 36822570)
1. Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks.
Chen JJ; Flanagan EP; Pittock SJ; Stern NC; Tisavipat N; Bhatti MT; Chodnicki KD; Tajfirouz DA; Jamali S; Kunchok A; Eggenberger ER; Nome MAD; Sotirchos ES; Vasileiou ES; Henderson AD; Arnold AC; Bonelli L; Moss HE; Navarro SEV; Padungkiatsagul T; Stiebel-Kalish H; Lotan I; Wilf-Yarkoni A; Danesh-Meyer H; Ivanov S; Huda S; Forcadela M; Hodge D; Poullin P; Rode J; Papeix C; Saheb S; Boudot de la Motte M; Vignal C; Hacohen Y; Pique J; Maillart E; Deschamps R; Audoin B; Marignier R
Am J Ophthalmol; 2023 Aug; 252():213-224. PubMed ID: 36822570
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes of first-ever episode of severe optic neuritis.
Galetta K; Ryan S; Manzano G; Chibnik LB; Balaban D; Prasad S; Chwalisz BK; Salazar-Camelo A; Conway S; Levy M; Matiello M
Mult Scler Relat Disord; 2022 Oct; 66():104020. PubMed ID: 35839615
[TBL] [Abstract][Full Text] [Related]
3. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.
Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
Mult Scler Relat Disord; 2021 Nov; 56():103222. PubMed ID: 34461572
[TBL] [Abstract][Full Text] [Related]
4. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders.
Bonnan M; Valentino R; Debeugny S; Merle H; Fergé JL; Mehdaoui H; Cabre P
J Neurol Neurosurg Psychiatry; 2018 Apr; 89(4):346-351. PubMed ID: 29030418
[TBL] [Abstract][Full Text] [Related]
5. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis.
Chen JJ; Flanagan EP; Bhatti MT; Tisavipat N; Jamali S; Kunchok A; Eggenberger ER; Nome MD; Sotirchos ES; Vasileiou ES; Henderson AD; Arnold AC; Bonelli L; Seleme N; Mejia-Vergara AJ; Moss HE; Padungkiatsagul T; Stiebel-Kalish H; Lotan I; Wilf-Yarkoni A; Hellmann MA; Vuppala A; Hodge D; Pittock SJ
Mult Scler Relat Disord; 2022 Dec; 68():104237. PubMed ID: 36252317
[TBL] [Abstract][Full Text] [Related]
6. The neuro-ophthalmological manifestations of NMOSD and MOGAD-a comprehensive review.
Moheb N; Chen JJ
Eye (Lond); 2023 Aug; 37(12):2391-2398. PubMed ID: 36928226
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
[TBL] [Abstract][Full Text] [Related]
8. Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein.
Ducloyer JB; Michel L; Wiertlewski S; Lebranchu P
Eur J Ophthalmol; 2019 Mar; 29(2):257-261. PubMed ID: 29972029
[TBL] [Abstract][Full Text] [Related]
9. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.
Chen JJ; Flanagan EP; Jitprapaikulsan J; López-Chiriboga ASS; Fryer JP; Leavitt JA; Weinshenker BG; McKeon A; Tillema JM; Lennon VA; Tobin WO; Keegan BM; Lucchinetti CF; Kantarci OH; McClelland CM; Lee MS; Bennett JL; Pelak VS; Chen Y; VanStavern G; Adesina OO; Eggenberger ER; Acierno MD; Wingerchuk DM; Brazis PW; Sagen J; Pittock SJ
Am J Ophthalmol; 2018 Nov; 195():8-15. PubMed ID: 30055153
[TBL] [Abstract][Full Text] [Related]
10. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis.
Stiebel-Kalish H; Rubarth K; Shouchane-Blum K; Tiosano A; Lotan I; Hellmann MA; Wilf-Yarkoni A; Bialer O; Flanagan EP; Pittock SJ; Bhatti MT; Schmitz-Hübsch T; Paul F; Asseyer S; Chen JJ
Sci Rep; 2022 Dec; 12(1):21312. PubMed ID: 36494385
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ
JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571
[TBL] [Abstract][Full Text] [Related]
12. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
13. Plasma exchange response in 34 patients with severe optic neuritis.
Deschamps R; Gueguen A; Parquet N; Saheb S; Driss F; Mesnil M; Vignal C; Aboab J; Depaz R; Gout O
J Neurol; 2016 May; 263(5):883-887. PubMed ID: 26964539
[TBL] [Abstract][Full Text] [Related]
14. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
[TBL] [Abstract][Full Text] [Related]
15. An update on optic neuritis.
Kraker JA; Chen JJ
J Neurol; 2023 Oct; 270(10):5113-5126. PubMed ID: 37542657
[TBL] [Abstract][Full Text] [Related]
16. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
17. Plasma exchange for acute optic neuritis in neuromyelitis optica or neuromyelitis optica spectrum disorder: a systematic review.
Naphattalung Y; Chuenkongkaew WL; Chirapapaisan N; Laowanapiban P; Sawangkul S
Ann Med; 2023 Dec; 55(1):2227422. PubMed ID: 37387119
[TBL] [Abstract][Full Text] [Related]
18. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
19. Visual Function Improvement after Plasma Exchange Therapy for Acute Optic Neuritis in Neuromyelitis Optica Spectrum Disorders: Case Series and Review.
Iancu R; Pirvulescu R; Anton N; Iancu G; Istrate S; Romanitan MO; Geamanu A; Popa Cherecheanu M
Diagnostics (Basel); 2024 Apr; 14(9):. PubMed ID: 38732279
[TBL] [Abstract][Full Text] [Related]
20. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
